Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 6

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 6
---
2023 and through
2024, we have been selling CyPath Lung tests to the Department of Defense (DOD) to conduct an observational study, “Detection
of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath Lung Assay,” and for
research and development on using bronchoalveolar lavage fluid as a biological sample to assess cardiopulmonary function and exercise
performance in military personnel post COVID-19 infection.

Corporate Information

We were incorporated in the State of Delaware on March
26, 2014. Our principal executive office is located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217, and our telephone number
at that address is (210) 698-5334. Our website address is https://www.bioaffinitytech.com/. Information contained on or that can be accessed
through our website is not incorporated by reference into this prospectus. Investors should not consider any such information to be part
of this prospectus.

Implications of Being an Emerging Growth Company and a Smaller Reporting Company

We qualify as an “emerging growth company”
(an “EGC”) as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As an EGC, for up to
five years, we may elect to take advantage of certain specified exemptions from reporting and other regulatory requirements that are otherwise
generally applicable to public companies. For example, these exemptions would allow us to:

| ● | present two, rather than three, years of audited financial statements with correspondingly reduced disclosure in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section (the “MD&A”) of this prospectus; |
| ● | defer the auditor attestation requirement on the effectiveness of our system of internal control over financial reporting;                                                                                                                            |
| ● | make reduced disclosures about our executive compensation arrangements; and                                                                                                                                                                           |
| ● | forego the adoption of new or revised financial accounting standards until they would be applicable to private companies.                                                                                                                             |

Certain of these reduced reporting requirements and
exemptions were already available to us due to the fact that we also qualify as a “smaller reporting company” under SEC rules.
For instance, smaller reporting companies are not required to obtain an auditor attestation and report regarding internal control over
financial reporting, to provide a compensation discussion and analysis, or to provide a pay-for-performance graph or CEO pay ratio